The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy

References

• Cetin B, Berk V, Kaplan M, et al. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma? Clin Genitourinary Cancer. 2013;11:141–148.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Kubo T, Komatsu K, et al. Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol. 2013;30:1–11.
   Web of Science ®Google Scholar
• Ohno Y, Nakashima J, Ohori M, et al. Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status. Int J Clin Oncol. 2014;19:139–145.
   PubMed Web of Science ®Google Scholar
• Fox P, Hudson M, Brown C, et al. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer. 2013;109:147–153.
   PubMed Web of Science ®Google Scholar
• Keizman D, Ish-Shalom M, Huang P, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. 2012;48:202–208.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhu Y, Gu W, et al. Pretreatment neutrophil‑to‑lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy. Int J Clin Oncol. 2016;21:373–378.
   PubMed Web of Science ®Google Scholar
• Dolan R, Lim J, McSorley S, et al. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep. 2017;7:16717.
   PubMed Web of Science ®Google Scholar
• Guthrie G, Charles K, Roxburgh C, et al. The systemic inflammation-based neutrophil–lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88:218–230.
   PubMed Web of Science ®Google Scholar
• Templeton A, McNamara M, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124.
   PubMedGoogle Scholar
• Coussens L, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.
   PubMed Web of Science ®Google Scholar
• Fitzgerald J, Nayak B, Shanmugasundaram K, et al. Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production. PLoS One. 2012;7:e30712.
   PubMed Web of Science ®Google Scholar
• Zhou L, Cai X, Liu Q, et al. Prognostic role of C-reactive protein in urological cancers: a meta-analysis. Sci Rep. 2015;5:12733
   PubMed Web of Science ®Google Scholar
• Négrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol. 2002;13:1460–1468.
   PubMed Web of Science ®Google Scholar
• Chen Z, Shao Y, Wang K, et al. Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysis. Onco Targets Ther. 2016;9:6701–6710.
   PubMed Web of Science ®Google Scholar
• Negrier S, Perol D, Menetrier-Caux C, et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6—from the Groupe Français d'Immunothérapie. JCO. 2004;22:2371–2378.
   PubMed Web of Science ®Google Scholar
• Motzer R, Bacik J, Murphy B, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. JCO. 2002;20:289–296.
   PubMed Web of Science ®Google Scholar
• Heng D, Xie W, Regan M, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study. JCO. 2009;27:5794–5799.
   PubMed Web of Science ®Google Scholar
• Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994;69:979–985.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93:387–391.
   PubMed Web of Science ®Google Scholar
• Templeton A, Knox J, Lin X, et al. Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. Eur Urol. 2016;2016:358–364.
   Web of Science ®Google Scholar
• Motzer R, Hutson T, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;368:722–731.
   Web of Science ®Google Scholar
• Hu K, Lou L, Ye J, et al. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ Open. 2015;5:e006404
   PubMed Web of Science ®Google Scholar
• Proctor M, Morrison D, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47:2633–2641.
   PubMed Web of Science ®Google Scholar
• Harrell FJ. Regression modeling strategies: with applications to linear models, logistic regression and survival analysis. New York (NY): Springer; 2001.
   Google Scholar
• Pencina MJ, D' Agostino RB, D' Agostino RB, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statist Med. 2008;27:157–172.
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565–574.
   PubMed Web of Science ®Google Scholar
• Anderson J, Cain K, Gelber R. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710–719.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Albiges L, Bensalah K. EAU guidelines: renal cell carcinoma. Proceedings of the EAU Annual Congress; Barcelona. EAU Guidelines Office, Arnhem (The Netherlands); 2019.
   Google Scholar
• Escudier B, Grünwald V, Gillessen S, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:706–720.
   PubMed Web of Science ®Google Scholar
• Vickers AJ. Prediction models: revolutionary in principle, but do they do more good than harm? J Clin Oncol. 2011;29:2951–2952.
   PubMed Web of Science ®Google Scholar
• Motzer R, Tannir N, McDermott D, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–1290.
   PubMed Web of Science ®Google Scholar
• Rini B, Plimack E, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116.
   PubMed Web of Science ®Google Scholar